MYH6 and hypertrophic cardiomyopathy: In utero injection of rAAV9 carrying the ABEmax-NG into the vitelline vein of E16 fetus resulted in about 25.3% correction of the pathogenic hypertrophic cardiomyopathy (HCM) mutation (R404Q/+ mutation; Myh6 c.1211C > T) in a mouse model of HCM, and reduced expression of mutant RNA, suggesting that ABEmax-NG has the potential to correct the HCM mutation in vivo